InvestorsHub Logo
Followers 1
Posts 17
Boards Moderated 0
Alias Born 10/27/2014

Re: None

Tuesday, 06/23/2015 11:02:12 AM

Tuesday, June 23, 2015 11:02:12 AM

Post# of 6723
I don´t think TKMR management is "confused".
I think there are two styles at loggerheads.

I don´t know if TKMR failed with the Ebola drug.
I don´t know what Horby has or has not done, & if what he did was done properly.
I don´t know if Horby has a hidden agenda.
I don´t know WTF is happening in Ebolaland.
Why all the blame on TKMR?
Why state as an 11th commandment that TKMR failed ??

We have Gisbert´s success with non human primates, why no mention of that by Horby?. Pr 4/22. I quote from a recent news article that came out AFTER the Horby Pr:

"...A scientist who has researched the drug in non-human primates expressed concern about the development, worrying that the decision might scupper a drug he believes shows a lot of promise.

“Knowing the mechanism of how the drug works, looking at all the non-human primate data we have, it’s hard for me to believe that the drug would not be beneficial if used under the right circumstance,” said Tom Geisbert, an Ebola virus expert at the University of Texas Medical Branch in Galveston. Geisbert does not have a financial interest in the drug.

He noted that an improved version of the drug that he and others tested in primates late last year showed greater success than the version that was being used in the trial in Sierra Leone.

And Geisbert said if TKM-Ebola is shelved, the hopes for Ebola treatment will rest almost entirely on one drug, ZMapp — the antibody cocktail created at Canada’s National Microbiology Laboratory in Winnipeg based on antibodies created in Winnipeg and at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Md.

“I can tell you (from) all the monkey studies that we do, you’ve got ZMapp and this one. And there’s a gigantic gap between those two drugs in monkeys and everything else.... You’re dropping off a cliff to the next thing down,” Geisbert said.,,"



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News